PADLOCK THERAPEUTICS
Padlock is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complexes in autoimmune diseases. Padlock intends to explore the full biological and therapeutic footprint of protein deimination by PADs. Padlock was founded by scientists at The Scripps Research Institute and members of the Atlas Venture Life Sciences Team. Padlock's investors include Atlas Venture, Johnson & Johnson, and MS Ventures. Padlock is a seed company operating out of the Atlas Venture office in Cambridge MA.
PADLOCK THERAPEUTICS
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.padlocktherapeutics.com
Total Employee:
10001+
Status:
Active
Contact:
(978) 381-9601
Total Funding:
37.68 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Content Delivery Network Google Universal Analytics New Relic Google Analytics IP Anonymization Add To Any Snowplow
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Cadent Therapeutics
Cadent Therapeutics develops novel medicines that tune and modulate brain rhythms for patients with serious neurological disease.
TeraImmune
TeraImmune is a developer of cell therapeutics created for autoimmune diseases and immune-related disorders.
Current Advisors List
Board_member
Founder
Investors List
Edward Kliphuis
Edward Kliphuis investment in Series A - Padlock Therapeutics
Atlas Venture
Atlas Venture investment in Series A - Padlock Therapeutics
Index Ventures
Index Ventures investment in Series A - Padlock Therapeutics
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation investment in Series A - Padlock Therapeutics
M Ventures
M Ventures investment in Series A - Padlock Therapeutics
Official Site Inspections
http://www.padlocktherapeutics.com
- Host name: 165.89.235.72
- IP address: 165.89.235.72
- Location: Trenton United States
- Latitude: 40.2187
- Longitude: -74.7404
- Metro Code: 504
- Timezone: America/New_York
- Postal: 08629
Padlocktherapeutics.com lookup results from whois.corporatedomains.com server:
- Domain created: 29th-Jan-2014
- Domain updated: 25th-Jan-2025
- Domain expires: 29th-Jan-2026 0 Years, 227 Days left
- Website age: 11 Years, 137 Days
- Registrar Domain ID: 1844708741_DOMAIN_COM-VRSN
- Registrar Url: http://cscdbs.com
- Registrar WHOIS Server: whois.corporatedomains.com
- Registrar Abuse Contact Email: domainabuse@cscglobal.com
- Registrar Abuse Contact Phone: 8887802723
- Name server:
- NS1.BMS.COM
- NS2.BMS.COM
- NS3.BMS.COM
- NS4.BMS.COM
More informations about "Padlock Therapeutics"
Padlock Therapeutics - Crunchbase Company Profile
When was the last funding round for Padlock Therapeutics? Padlock Therapeutics closed its last funding round on Dec 18, 2014 from a Series A …See details»
Padlock Therapeutics, Inc. Company Profile | Cambridge, MA ...
Find company research, competitor information, contact details & financial data for Padlock Therapeutics, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Padlock Therapeutics 2025 Company Profile: Valuation, …
Padlock Therapeutics General Information Description. Provider and developer of novel drugs. This company is focused on discovering novel therapeutics that …See details»
Padlock Therapeutics - Products, Competitors, Financials, …
Padlock Therapeutics is a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases. Use the CB …See details»
Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.
Mar 23, 2016 Bristol-Myers Squibb Company (NYSE:BMY) and Padlock Therapeutics, Inc. announced today that the companies have signed a definitive agreement under which Bristol …See details»
Companies - Medicxi
Padlock Therapeutics - Acquired by BMS. Padlock is taking a whole new approach to treating autoimmune diseases, by developing new drugs that block the protein-arginine deiminases …See details»
Padlock Therapeutics Inc. - life-sciences-europe.com
Jan 1, 2014 Padlock Therapeutics is a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases. The …See details»
Padlock Therapeutics Inc - Company Profile and News
Company profile page for Padlock Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Padlock Therapeutics - VentureRadar
Padlock Therapeutics is a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases. The company …See details»
Padlock Therapeutics
Padlock Therapeutics - Acquired by BMS. Padlock is taking a whole new approach to treating autoimmune diseases, by developing new drugs that block the protein-arginine deiminases …See details»
Padlock Therapeutics - M Ventures
Padlock Therapeutics is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune …See details»
Padlock Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Padlock Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 news, and 1 literature.See details»
Padlock Therapeutics - Overview, News & Similar companies
Padlock Therapeutics. Business Services · Massachusetts, United States · 32 Employees. View Company Info for Free. About. Headquarters 200 Cambridgepark Dr, Cambridge, …See details»
Padlock Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Dec 18, 2014: ... Series A - …See details»
Padlock Therapeutics - Atlas Venture
May 7, 2025 © 2025 ATLAS VENTURE, All Rights Reserved. Site by Show + Tell. Contact; Privacy PolicySee details»
Padlock Therapeutics - Chemical & Engineering News
Nov 2, 2015 Find out what Padlock Therapeutics has been up to since it appeared on C&EN’s 2015 Top Start-ups List by clicking here. Chemical & Engineering News ISSN 0009-2347See details»
Bristol-Myers bags biotech upstart Padlock in $600M autoimmune …
Mar 23, 2016 Bristol-Myers Squibb has struck a $600 million deal to buy out the biotech startup Padlock Therapeutics and its autoimmune R&D platform. | Bristol-Myers Squibb has struck a …See details»
BMS buys autoimmune biotech Padlock for up to $600 million
Mar 23, 2016 Bristol-Myers Squibb is to buy US biotech Padlock Therapeutics, which aims to create treatments for serious autoimmune diseases, in a deal worth up to $600 million. BMS …See details»
BMS Completes Acquisition of Padlock Therapeutics
Apr 5, 2016 Bristol-Myers Squibb has completed its previously announced planned acquisition of Padlock Therapeutics, Inc, a privately held, Cambridge, Massachusetts-based biotechnology …See details»
Bristol Myers Squibb - Bristol-Myers Squibb Completes Previously ...
Apr 1, 2016 Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has completed the previously announced planned acquisition of Padlock Therapeutics, Inc. . The …See details»